Table II. Outcome for All Patients According to the Survivin-2B/ΔEx2 Ratio.

	Survivin-2B/ΔEx2 <1 (n = 68)		Survivin-2B/ΔEx2 ≥ 1 (n = 22)
	N	% ± 2SE%	N	% ± 2SE%	P-value
5-year OS from study entry	68	60 ± 12	22	36 ± 21	0.011
5-year EFS from study entry	68	53 ± 12	22	23 ± 18	0.001
5-year OS from end of course 1	59	65 ± 13	10	60 ± 31	0.665
5-year DFS from end of course 1	59	57 ± 13	10	40 ± 31	0.323
5-year RR from end of course 1	59	31 ± 12	10	60 ± 31	0.061
5-year TRM from end of course 1	59	12 ± 9	10	0 ± 0	0.263
5-year OS from end of course 2	47	70 ± 14	12	50 ± 29	0.134
5-year DFS from end of course 2	47	61 ± 14	12	33 ± 27	0.066
5-year RR from end of course 2	47	32 ± 14	12	58 ± 28	0.056
5-year TRM from end of course 2	47	6 ±7	12	8 ± 16	0.834

OS, overall survival; EFS, event-free survival; DFS, disease-free survival; RR, relapse rate; TRM, treatment-related mortality; SE, standard error.